CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix
Arno H. M. Moons, MD*,*,
Ron J. G. Peters, MD, PhD*,
Nick R. Bijsterveld, MD*,
Jan J. Piek, MD, PhD*,
Martin H. Prins, MD, PhD ,
George P. Vlasuk, PhD ,
William E. Rote, PhD and
Harry R. Büller, MD, PhD
* Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
Department of Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Corvas International, Inc., San Diego, California, USA
Manuscript received January 23, 2003;
revised manuscript received March 5, 2003,
accepted March 12, 2003.
* Reprint requests and correspondence: Dr. Arno H. M. Moons, Department of Cardiology, Academic Medical Center, Room F3-241, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
A.H.Moons{at}amc.uva.nl
OBJECTIVES: We investigated the safety and pharmacodynamics of escalating doses of recombinant nematode anticoagulant protein c2 (rNAPc2) in patients undergoing elective coronary angioplasty.
BACKGROUND: Recombinant NAPc2 is a potent inhibitor of the tissue factor/factor VIIa complex, which has the potential to reduce the risk of thrombotic complications in coronary artery disease.
METHODS: In a randomized, double-blinded, dose-escalation, multicenter trial, 154 patients received placebo or rNAPc2 at doses of 3.5, 5.0, 7.5, and 10.0 µg/kg body weight as a single subcutaneous administration 2 to 6 h before angioplasty. All patients received aspirin, unfractionated heparin during angioplasty, and clopidogrel in case of stent implantation.
RESULTS: Minor bleeding rates for the doses 3.5 to 7.5 µg/kg were comparable to that with placebo (6.7%), whereas an incidence of 26.9% was observed at the 10.0-µg/kg dose level (p < 0.01). Major bleedings occurred in the 5.0-µg/kg (n = 3) and 7.5-µg/kg (n = 1) dose groups. The three patients in the 5.0-µg/kg dose group also received a glycoprotein IIb/IIIa receptor inhibitor at the moment of major bleeding. Systemic thrombin generation, as measured by prothrombin fragment 1+2 (F1+2), was suppressed in all rNAPc2 dose groups to levels below pretreatment values for at least 36 h. In the placebo group, a distinct increase of F1+2 levels was observed following cessation of heparin.
CONCLUSIONS: Inhibition of the tissue factor/factor VIIa complex with rNAPc2, at doses up to 7.5 µg/kg, in combination with aspirin, clopidogrel, and unfractionated heparin appears to be a safe and effective strategy to prevent thrombin generation during coronary angioplasty.
|
Abbreviations and Acronyms
| | F1+2 | = prothrombin activation fragment 1+2 | | FCT | = femoral compression time | | GP | = glycoprotein | | IQR | = interquartile range | | MI | = myocardial infarction | | PCI | = percutaneous coronary intervention | | rNAPc2 | = recombinant nematode anticoagulant protein c2 | | TAT | = thrombin/antithrombin complexes | | TF | = tissue factor | | UFH | = unfractionated heparin |
|
This article has been cited by other articles:
|
|
|
|
 
E. I. Tucker, U. M. Marzec, T. C. White, S. Hurst, S. Rugonyi, O. J. T. McCarty, D. Gailani, A. Gruber, and S. R. Hanson
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI
Blood,
January 22, 2009;
113(4):
936 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama
New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
234S - 256S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mackman, R. E. Tilley, and N. S. Key
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis
Arterioscler Thromb Vasc Biol,
August 1, 2007;
27(8):
1687 - 1693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano, S. D. Wiviott, P. H. Stone, D. I. Simon, M. J. Schweiger, A. Bouchard, M. A. Leesar, M. A. Goulder, S. R. Deitcher, C. H. McCabe, et al.
Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM-TIMI-32 Trial
J. Am. Coll. Cardiol.,
June 26, 2007;
49(25):
2398 - 2407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Additional Information
JAMA,
March 15, 2006;
295(11):
E7 - E14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Steffel, T. F. Luscher, and F. C. Tanner
Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications
Circulation,
February 7, 2006;
113(5):
722 - 731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
September 6, 2005;
46(5):
906 - 919.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Pengo
New trends in anticoagulant treatments
Lupus,
September 1, 2005;
14(9):
789 - 793.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow, S. A. Murphy, C. H. McCabe, N. Mackman, H. C. Wong, E. M. Antman, and on behalf of the PROXIMATE-TIMI 27 Investigators
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
Eur. Heart J.,
April 1, 2005;
26(7):
682 - 688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F Viles-Gonzalez, V. Fuster, and J. J Badimon
Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences
Eur. Heart J.,
July 2, 2004;
25(14):
1197 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Shapiro
Treating Thrombosis in the 21st Century
N. Engl. J. Med.,
October 30, 2003;
349(18):
1762 - 1764.
[Full Text]
[PDF]
|
|
|
|
